ICMJE DISCLOSURE FORM

| Date: | 9/24/2022 |
|-------------------------------|---|
| Your Name: | Charles A. Czeisler |
| Manuscript Title: | : Shifting Mortality Dynamics in the United States During the COVID-19 Pandemic as Measured by Years of Life Lost |
| Manuscript Number (if known): | M22-2226 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial planning | of the work |
| 1 | All support for the present | □ None | |
| | manuscript (e.g., funding, provision of study materials, | US Centers for Disease Control and Prevention | Institutional support for this work was provided to the Mass General Brigham through a subcontract from NTouch-Bct Strategies, LLC |
| | medical writing, article processing charges, etc.) No time limit for | Cephalon, Inc. | Prof. Charles Czeisler serves as the incumbent of an endowed professorship provided to Harvard Medical School by Cephalon, Inc. in 2004, which provided institutional support for this work. |
| | this item. | National Institute of Occupational Safety and Health R01-OH-011773 | ClicInstitutional support for this work was provided to the Mass General Brigham through a government grant awarded to the Brigham and Women's Hospital that provides partial salary support to Prof. Charles Czeislerk the tab key to add additional rows. |
| | | Time frame: past 36 month | ns |
| 2 | Grants or contracts from | □ None | |
| | any entity (if not indicated in item | Delta Airlines | Institutional support for Quality Improvement Initiative |
| | #1 above). | Jazz Pharmaceuticals PLC Inc | Institutional education support to Harvard Medical School Division of Sleep Medicine; institutional support to Brigham and Women's Hospital for clinical research trials on which Dr. Czeisler is the Principal Investigator |

| | tution) |
|--|--|
| Axome Therapeutics, Inc. Institutional support to Bright Hospital for clinical research t Czeisler is the Principal Invest | rial on which Dr. igator |
| Philips Respironics Inc Institutional education/resear Harvard Medical School and B Women's Hospital that suppo contract with Qualtrics LLC to earlier waves of The COPE Init | Brigham and orted in part the administer |
| Puget Sound Pilots Institutional support for Quali | · |
| Regeneron Pharmaceuticals and Sanofi SA Institutional research support Brigham and Women's Hospit projects on which Dr. Czeisler Investigator | tal for research |
| ResMed Institutional educational Gran Sleep and Health Education Pr Harvard Medical School Divisi Medicine (which Dr. Czeisler of | rogram of the on of Sleep |
| Teva Pharmaceuticals Industries Ltd Institutional educational Gran Sleep and Health Education Pr Harvard Medical School Divisi Medicine (which Dr. Czeisler of | nt funding to the rogram of the ion of Sleep |
| Vanda Pharmaceuticals Institutional educational Gran Sleep and Health Education Pl Harvard Medical School Divisi Medicine (which Dr. Czeisler o | rogram of the on of Sleep |
| Royalties or licenses None | |
| Philips Respironics, Inc. I assigned all rights to Philips Respironics although I have not consulted in more than 10 years, I continuously payments on sales of the Actiwatch-Spectrum devices | d with the company nue to receive |
| | |
| 4 Consulting fees None | |
| With Deep, Inc Personal consultancy fees | |
| Vanda Pharmaceuticals Personal consultancy fees Signos, Inc Personal consultancy fees | |
| Signos, Inc Personal consultancy fees Bryte Foundation Personal consultancy fees | |
| Simpson & Simpson Personal consultancy fees | |
| 5 Payment or honoraria for None | |
| lectures, presentations, Associated Professional Sleep Societies Honorarium for Thomas Roth Excellence at SLEEP 2022 annuments of the state of the s | |
| speakers bureaus, Massachusetts Medical Society Honorarium for writing Perspe | |
| manuscript Writing or National Sleep Foundation Chair, Sleep Timing and Varial Panel | bility Consensus |
| educational | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|--------|---|--|---|
| | | Teva Pharma Australia | Honorarium for delivering series of lectures on Shift Work Disorder via Zoom |
| | | University of Colorado | Honorarium for delivering lecture |
| 6 | Payment for expert testimony | □ None | |
| | | Atty Yolanda Huang and Kaitlyn Murphy. Esq. | Norbert et al.vs. San Francisco County Sheriff's |
| | | Deputy City Attorney, City of San Francisco | Department et al./personal fees |
| | | Clement Law Firm | Dally et al vs. C&J Energy Services et al/personal fees |
| | | Law Office of Daniel D. Horowitz III, P.C. | Amaya et al. vs. C&J Energy Services, Inc et al./personal fees |
| | | Segal Law Firm | Hammett et al. vs. Enterprise Rent-A-Car et al./personal fees |
| | | Zehl and Associates, P.C. | Various matters |
| | | Paul, Weiss, Rifkind, Wharton & Garrison LLP | Expert witness services regarding Patent Litigation (Vanda Pharmaceuticals Inc., Plaintiff, vs. Teva Pharmaceuticals USA, Inc./ and Apotex Corp., MSN Pharmaceuticals Inc and MSN Laboratories Private Limited) |
| | | The Armstrong Firm, PLLC and Rabb and Rabb | Torres et al., vs. Top Run Energy Services, LLC |
| | | PLLC | and Butch's Rat Hole & Anchor Service, |
| | | | Inc./personal fees |
| | | Shaked Law Firm, P.A. | Faneite Law Formvs. Penske Logistics |
| | | Haglund Kelley LLP | Rate Commission Hearing Testimony for Puget |
| | | Law Offices of James L Mitchell | Sound Pilots' works scheduling/personal fees Peake vs. Fevid Transport et al. |
| | | Law Offices of James E Witterier | reace vs. revio transport et al. |
| 7 | Support for attending | None | |
| | meetings and/or travel | Stanley Ho Medical Development Foundation | Travel to Macao and Hong Kong |
| | traver | Associated Professional Sleep Societies | Travel support for Thomas Roth Lecture of Excellence at SLEEP 2022 annual meeting |
| | | | Excellence at SEEEF 2022 annual meeting |
| 8 | Patents planned, | None | |
| | pending | | |
| | | | |
| | | | |
| | | | |
| 9 | Participation on a Data Safety Monitoring | None ■ | |
| | Board or | | |
| | Advisory Board | | |
| | , | | |
| 10 | Leadership or | □ None | |
| | fiduciary role in other board, | LIK Biotocko ologo over d Biologica C | Advisory Doord marries |
| | society, | UK Biotechnology and Biological Sciences Research Council | Advisory Board member |
| | committee or | Institute of Digital Media and Child Development | Advisory Board member |
| | advocacy group, | Klarman Family Foundation | Advisory Board member Advisory Board member |
| | paid or unpaid | Journal of Biological Rhythms | Advisory Board Member Advisory Board Member |
| \Box | • | 12/12/2021 | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---------------------------------------|--|---|
| 11 | Stock or stock options | □ None | |
| | | Vanda Pharmaceuticals, Inc. | Dr. Czeisler has equity interest |
| | | With Deep, Inc. | Dr. Czeisler has equity interest |
| | | Signos, Inc. | Dr. Czeisler has equity interest |
| | | | |
| | | | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | , |
| | materials, drugs, medical writing, | Johnson & Johnson | Institutional educational gift to Brigham and Women's Hospital |
| | gifts or other | Mary Ann and Stanley Snider via Combined Jewish | Institutional educational gift to Brigham and |
| | services | Philanthropies | Women's Hospital |
| | | Alexandra Drane | Institutional research gift to Brigham and |
| | | | Women's Hospital |
| | | DR Capital | Institutional research gift to Brigham and |
| | | | Women's Hospital |
| | | Harmony Biosciences LLC | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | ResMed, Inc. | Institutional educational equipment gift to |
| | | | Harvard University |
| | | Vanda Pharmaceuticals, Inc | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Eisai Co., LTD | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Jazz Pharmaceuticals | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Idorsia Pharmaceuticals LTD | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Sleep Number Corp. | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Apnimed, Inc. | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Avadel Pharmaceuticals | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Axome Therapeutics, Inc. | Institutional educational gift to Brigham and |
| | | | Women's Hospital |
| | | Bryte Foundation | Institutional gift to support education and |
| | | | research to Brigham and Women's Hospital |
| | | f.lux Software, LLC | Institutional gift to support education and |
| | | | research to Brigham and Women's Hospital |
| | | Stuart F. and Diana L. Quan Charitable Fund | Institutional gift to support education and |
| | | Casay Faldmann Fayy dation | research to Brigham and Women's Hospital |
| | | Casey Feldman Foundation | Institutional gift to support education and |
| | | Doman Cathalia Analalia and af D | research to Brigham and Women's Hospital |
| | | Roman Catholic Archdiocese of Boston | Institutional gift to support education and |
| | | Communication | research to Brigham and Women's Hospital |
| | | Summus, Inc. | Institutional gift to support education and |
| | | Talada Pharmana C. J.C. 175 | research to Brigham and Women's Hospital |
| | | Takeda Pharmaceutical Co., LTD | Institutional gift to support education and |
| | | | research to Brigham and Women's Hospital |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|-----------|--|--|
| | | Philips Respironics | Institutional gift to support education and research to Brigham and Women's Hospital |
| | | Abbaszadeh Foundation | Institutional gift to support education and research to Brigham and Women's Hospital |
| | | Sharon and John Loeb | Institutional gift to support education and research to Brigham and Women's Hospital |
| | | CDC Foundation | Institutional gift to support research to Brigham and Women's Hospital |
| | | Centers for Disease Control and Prevention | Institutional gift to support research to Brigham and Women's Hospital |
| | | ResMed, Inc. | Institutional educational, research and equipment gifts to Harvard University |
| | | | |
| 13 Other financial or non-financial None | | | |
| | interests | | Dr. Czeisler's interests were reviewed and are managed by the Brigham and Women's Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. Though none of the interests in sections 2-7 are directly related to the current manuscript, in the interest of full disclosure, they are reported herein. |
| | | | |
| Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

ICMJE DISCLOSURE FORM

| Date: | 9/21/2022 |
|-------------------------------|---|
| Your Name: | Mark Czeisler |
| Manuscript Title: | Years of Life Lost in the United States During the COVID-19 Pandemic, March–December in 2020 and 2021 |
| Manuscript Number (if known): | M22-2226 |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

| l | | Name all entities with whom you have this relationship or indicate none (add rows as needed | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
|---|---|---|---|--|
| | | Time frame: Since the initial plannin | g of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | None None | Click the tab key to add additional rows. | |
| | tilis item. | | | |
| | | Time frame: past 36 months | | |
| 2 | Grants or contracts from | | | |
| ; | any entity (if not indicated in item #1 above). | US Centers for Disease Control and Prevention | Contract with Massachusetts General Brigham for The COVID-19 Outbreak Public Evaluation (COPE) Initiative public health surveillance activity | |
| | | CDC Foundation | Contract with Monash University for The COVID-19 Outbreak Public Evaluation (COPE) Initiative public health surveillance activity | |
| | | WHOOP, Inc. | Gift to Monash University for The COVID-19 Outbreak Public Evaluation (COPE) Initiative public health surveillance activity | |
| | | Hopelab, Inc. | Gift to Monash University for The COVID-19 Outbreak Public Evaluation (COPE) Initiative public health surveillance activity | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| | | The Kinghorn Foundation | Funding for a Fulbright Scholarship |
| 3 | Royalties or licenses | None ■ | |
| 4 | Consulting fees | □ None Vanda Pharmaceuticals Nythemeron, LLC | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None None | |
| 6 | Payment for expert testimony | None Non | |
| 7 | Support for attending meetings and/or travel | None None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety | ⊠ None | |

| | | | e all entities with whom you have this onship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|------|--|---|
| | Monitoring Board or Advisory Board | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | | None | |
| 11 | Stock or stock options | With | None n Deep | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | | None | |
| 13 | Other financial or non-financial interests | | None | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | |
| \boxtimes | I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | |

3 12/13/2021 ICMJE Disclosure Form